Company news

Palisade Bio, Inc. news in 2021

Palisade Bio, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus

December 7, 2021

Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035

November 29, 2021

Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Including Nick McCoy, Vice President of Clinical Operations

November 22, 2021

Palisade Bio Reports Third Quarter Financial Results

November 14, 2021

Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders

October 21, 2021

Palisade Bio Reports Second Quarter Financial Results and Provides Business Update

August 23, 2021

Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center

August 19, 2021

Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery

July 28, 2021

Palisade Bio Enters into Worldwide In-Licensing Agreement with University of California for Technology to Support Target Identification, Drug Discovery, and Clinical Development

July 12, 2021

Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical Adhesions

June 14, 2021

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery

May 12, 2021

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China

May 6, 2021

Decks in 2021